Tenax Therapeutics, Inc. (TENX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the 10X Therapeutics virtual KOL call. At this time, all participants are in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. A question and answer session will follow the KOL panel discussion. To ask a question, you may press star, then one on your touchtone phone. To withdraw your question, please press star, then two. Please note, today's call is being recorded. I'd now like to turn the call over to Chris Giordano, President and CEO of 10X Therapeutics. Please go ahead. Thank you, Betsy, and welcome everyone to an in-depth discussion of the science behind 10X's ongoing development program in PHF-PET. We're developing TNX-103, an oral formulation of levocimendin, which we believe has the potential to to be a first-in-class treatment for PHHPAC. TNX103 is currently in late stage development in the phase three level study with top line data expected in the second half of 2026, and also level two, a global phase three study on track to initiate this year. TNX is not alone in focusing on patients with the most common form of PH for which no drug is approved, And it's great to see more and more investigational strategies being evaluated in these patients, considering the grave unmet need that patients with PHFF face. At 10x, we get a lot of questions about the differences between our PHFF program and work done in the space by other researchers. For example, we focus on a different physiologic target than other drugs in development. We have a unique mechanism of action. And aspects of our trial designs are really different to other PHSPF trials, et cetera. So we thought we'd spend an hour today. We thought it would just be good to dig into these differences and ...